

Oligonucleotide based therapeutic strategies for tackling schizophrenia - A systematic review



Jabir PK¹, Sumina Cheriyan², Pooja Korath³, Sai Sailesh Kumar Goothy⁴

¹Associate Professor, Department of Physiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, P.O. Thandalam, Chennai, Tamil Nadu, ²Associate Professor, Department of Biochemistry, ³Assistant Professor, Department of Physiology, Dr. Moopen's Medical College, Wayanad, Kerala, ⁴Associate Professor, Department of Physiology, NRI Institute of Medical Sciences, Vizag, Andhra Pradesh, India

Submission: 22-06-2022

Revision: 23-08-2023

Publication: 01-10-2023

ABSTRACT

Schizophrenia is a serious mental disorder that affects the quality of life of patients, and the cure for the disease is yet a mirage. Drugs are having side effects and not giving satisfying results. Recently, genes have been isolated. The role of oligonucleotide in many diseases, such as multiple sclerosis and cancer, is promising. Since oligonucleotides can modulate gene expression, these molecules can be used as drugs in several conditions which are beyond the usage of conventional drugs. They are also important in the future as therapeutic drugs like rare diseases, which are genetic and in which specific sequences of genes are to be addressed. Since they can bind to Cas9 protein, they can be used for gene editing. Even though the delivery of oligonucleotides faces some limitations, they can be delivered to targets using chemical modification, bioconjugation, and nanotechnology. Overall, they can be used in research, diagnosis, and therapy. Since they are small in size, they have target affinity. They are also cheap to synthesize and more stable than antibodies. This review summarizes the pathophysiology of schizophrenia and its current treatment, recent updates, and insights into the role of oligonucleotide and its regulation of genes. In this article, we also reviewed the genetics of schizophrenia and the possible application of oligonucleotides in the therapeutics of schizophrenia. The introduction of oligonucleotides in the therapy of schizophrenia can be a possible strategy that can be put forward in the future for the management of schizophrenia.

Key words: Oligonucleotide; Aptamer; miRNA; Schizophrenia

INTRODUCTION

Around 1% of world's population is affected with Schizophrenia which is a debilitating psychiatric disorder. The incidence is about 1.5/10,000 people. The global age-standardized point prevalence of schizophrenia is estimated to be 0.28%.¹ Suicidal tendencies present in this disorder up to 10–15% and one-third of mental hospital beds are occupied with schizophrenia. Risk of patients harming themselves and others, failure to maintain personal relationships, low education, and employment status are few among the problems met by schizophrenic patients. As per the World Health Organization ranking in

1990, schizophrenia is placed as the 10th-leading cause of disability with annual cost of 19 billion US dollars. Public assistance from government social security systems is required for two-thirds of people.²

Adverse effects of antipsychotics and poor patient compliance and relapse of disease makes the management more difficult. Poor compliance may be also due to stoppage of drugs by patients themselves when they get good response to treatment.³ Some doctors considering side effects may stop treatment. Since there is no cure for schizophrenia and discontinuations of medicines by patients are frequent, relapse rates are high.³ Above

Access this article online

Website:

<http://nepjol.info/index.php/AJMS>

DOI: 10.3126/ajms.v14i10.55972

E-ISSN: 2091-0576

P-ISSN: 2467-9100

Copyright (c) 2023 Asian Journal of Medical Sciences



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Address for Correspondence:

Dr. Jabir P.K., Associate Professor, Department of Physiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, P.O. Thandalam, Chennai, Tamil Nadu - 602 105, India. **Mobile:** +91-9447269969, **E-mail:** jabspk@gmail.com

information shows the high need of treatment for schizophrenia.

PATHOPHYSIOLOGY OF SCHIZOPHRENIA

Although the pathogenesis of the disorder is unknown, it is almost certain that schizophrenia represents a syndrome comprised multiple diseases that present with similar signs and symptoms. Schizophrenia is thought to occur when a region of the brain called the prefrontal cortex becomes abnormally active because interneurons, which connect neuron circuits or neuron groups, become dysfunctional and stop regulating neuronal activity.⁴ Pathophysiology of schizophrenia centered on the dopamine hypothesis and dopamine D2 receptor (DRD2) blockade is the key neurobiological mechanism on which antipsychotics were developed.⁵ But tolerances towards drugs are hindrances for the treatment. Studies with lower doses of haloperidol in the first episode of the disease compared with multi-episode patients found that clinical responses are lower in multi-episode patients, pointing toward the tolerance of antipsychotic drugs.⁶ Even though after a long five decades since the drug discovery, current drug treatments are found to be showing low prognosis, and all drugs have the same mechanism of action by DRD2 blockade.⁷ Role of proteins like hippocampal parvalbumin (PV) and their genes are well evident now in pathogenesis of schizophrenia.⁸

The neurons that secrete dopamine have pacemaker properties. Hence, it is spontaneous and also depolarizing is slow in manner. This maintains basal activity. GABAergic neurons alter this pacemaker firing into a slow-irregular firing pattern. In case of response to rapid phasic stimuli tonic spontaneous discharge is important. Meanwhile, if the stimulus is a potential threat or a reward-related event, dopaminergic neurons transit to a phasic burst firing pattern (Figure 1).

In patients with schizophrenia, there is an overdrive in the area of hippocampus. This finally results in increased tonic dopaminergic neuronal firing and hyper responsive state in patients with schizophrenia.

Usually, there are strong inhibitions to pyramidal neurons. This occurs by GABAergic interneurons. PV-labeled GABAergic interneurons in the ventral subiculum are having glutamate as their neurotransmitters acting on NMDA receptors. This PV-pyramidal neuron action is needed for rhythmic activity. If there is a loss of PV interneurons, there can be hyperactivity and dysregulation in rhythm of pyramidal neurons. This can be one of the causes of schizophrenia. In the case of schizophrenia, there


is a loss of a large number of PV interneurons, causing the pyramidal neurons to be hyperactive and dysrhythmic (Figure 2).

MATERIALS AND METHODS

Searches of the articles from pubmed.com, Cochrane library, British medical journal.com, frontiersin.org, and online standardized journals have been done. Search keys were oligonucleotide, schizophrenia, aptamers, and miRNA. They were put in Boolean search.

RESULTS

A total of 737 articles were identified after the search. 501 were removed since those records were without free full text. The rest 236 were screened and assessed for eligibility and further 225 articles were removed since they were not relevant to the topic. 11 articles were included for the discussion.



CURRENT TREATMENTS IN SCHIZOPHRENIA

The methods of treatment of schizophrenia are classified as the first (mainly DRD2 antagonists), second (multi-target antagonists with greater antagonism at serotonin 5-HT_{2A} receptor than at DRD2) and third-generation antipsychotics represented, for example, by aripiprazole, brexpiprazole and cariprazine.^{9,10} Reelin, a large extracellular glycoprotein which controls neuronal migration and positioning neurons, found to be reduced to half of normal concentration in prefrontal cortex, temporal cortex, hippocampus, caudate nucleus and cerebellum in schizophrenic patients.¹¹ Current drug treatments target D2/3 receptors in the post synaptic membrane. However, it is well evident now there lays pathogenic abnormality in dopaminergic system in pre-

synaptic membrane affecting the capacity of dopamine synthesis, baseline synaptic dopamine levels and dopamine release. Even molecular imaging studies *in vivo* shows that increased dopamine synaptic availability and increased pre-synaptic dopamine synthesis in the striata of patients with psychosis.¹² Since present drug treatments act on these D2/3 receptors they fail to reverse these pathophysiology mentioned above. So there is an urgent need in development of drugs that modulate pre-synaptic dopamine synthesis and its release.⁷

Since the pathophysiology of schizophrenia can be explained by dysfunction in striatal pre-synaptic excessive dopaminergic discharge; targeted drug delivery like aptamers may be promising in the cure of the disease. Aptamers are synthetic single-stranded DNA or RNA molecules having of 60–100 nucleotides. These are selected by a process known as systematic evolution of ligands by exponential enrichment.¹³

Why aptamers?

Oligonucleotide aptamers are short, synthetic, single-stranded DNA or RNA able to recognize and bind to a multitude of targets ranging from small molecules to cells. Aptamers have emerged as valuable tools for fundamental research, clinical diagnosis, and therapy. Due to their small size, strong target affinity, lack of immunogenicity, and ease of chemical modification, aptamers are an attractive alternative to other molecular recognition elements, such as antibodies. Aptamers are easier to synthesize, offer little to no batch-to-batch variation, and are typically more chemically stable than antibodies. Furthermore, the binding functionality of oligonucleotide aptamers can be regulated through hybridization with their complementary sequences, providing an extra layer of therapeutic control.¹⁴ In the diagnostic field they are used in the detection of antigens and toxins of bacteria and as biomarkers in cancer.¹⁵ They may be used as an alternative to monoclonal antibodies. In 1997, the first RNA aptamer for DA (dopamine) was selected.¹⁶ The authors proposed that DA interacts with a binding domain in the aptamer formed by the association of two stem-loop motifs. The first commercialized aptamer which was approved by FDA is macugen. This is effective in age-related macular degeneration by binding against vesicular endothelial growth factor 165. Aptamer are also developed against proteins such as cancer proteins, blood clotting proteins, antibody E, autoantibodies involved in autoimmune diseases. Promising results are coming in the field of treating viral infections where aptamers have been developed against viruses.¹³

Researchers are now interested in this molecule, and many modifications in them to improve their properties and potency, like affinity and potency, are undergoing.¹⁷ A study was conducted in which DNA aptamer with binding




Figure 1: Tonic and phasic release of dopamine neurotransmitter. (Source: Anthony A. Grace. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Published in final edited form as: *Nat Rev Neurosci*. 2016 August; 17(8): 524–532. doi:10.1038/nrn.2016.57)

affinity for dopamine is injected into the nucleus accumbens and its effect on the MK-801-induced deficit in extinction responding is determined.¹⁸ Therapeutic role of aptmers in neurological disorders is well documented.¹⁹ Studies shown aptamers may be used as diagnostic and therapeutic tools in Alzheimer's disease by targeting B1-CT, the short cytoplasmic tail of BACE1 protein, and beta A4, an amyloid peptide.²⁰ Certain aptamers *in vitro* competitively binds to Nogo-66 receptor has implicated in elongation of axons.²¹ In cell culture aptamers shown to displace cocaine from the nicotinic type of acetylcholine receptor.²² Even adenosine phosphates of brain extracts of rats can be detected by an aptamer-gold nanorod assay. Limitations of usage of aptamers include difference in aptamers produced in same laboratory for same target. To overcome this standardization of kits and protocols has to be done.²³

GENETICS OF SCHIZOPHRENIA

No single gene is necessary or sufficient to determine the disease, rather, a combination of risk genes with small effects describe the highly heterogeneous genetic basis of schizophrenia.²⁴ Recent studies in epigenetics of schizophrenia




Figure 2: The pathophysiology of symptoms of schizophrenia. Interaction between PV interneuron and pyramidal neuron is shown. (Source: Anthony A. Grace. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Published in final edited form as: *Nat Rev Neurosci*. 2016 August; 17(8): 524–532. doi:10.1038/nrn.2016.57)




Figure 3: Role of Dysbindin in pos synaptic functions. (Source: Haitao Wang, Jiangping Xu, Philip Lazarovici, Wenhua Zheng. Dysbindin-1 Involvement in the Etiology of Schizophrenia. *Int J Mol Sci*. 2017 Oct; 18(10): 2044. Published online 2017 Sep 22. doi: 10.3390/ijms18102044)

show pathogenesis is related to methylation of DNA, modification of histones and microRNA.²⁵ Susceptible genes include neuregulin, dysbindin, catechol-O-methyl transferase (COMT), DISC1, the regulator of G protein signaling 4 (RGS4), GRM3, G and 72.²⁶ COMT has two types S COMT and MB COMT. MB COMT more important in schizophrenia. Many of these genes are involved in neuronal development dysregulation of which causes pathogenesis of schizophrenia and these genes are also involved in the ongoing process of schizophrenia in adulthood.²⁶ Dysbindin has role in post-synaptic functions, which include trafficking and tethering of receptors (including NMDA, nicotinic, and GABA_A receptors) and signal transduction proteins.²⁶ Dysbindin reduction in post synapses causes schizophrenia (Figure 3).²⁷

Transcription of miRNA gene by RNA-polymerase II produces primary miRNA (pri-miRNA). Complex of Drosha and DGCR8 (Di George syndrome Critical region 8) processes pri-miRNA into pre-miRNA. Pre-miRNA is transported into

cytoplasm and again processed by endonuclease Dicer to miRNA ~ 22 nucleotide long. Then, one of these strands is loaded into RNA-induced silencing complex. miRNA can bind to target sequence on untranslated regions (3' – UTR) of mature mRNAs and results in degradation of mRNA or repression of its translation. By this mechanism, miRNA can achieve post-translational silencing (Figure 4).

Single-nucleotide polymorphisms (SNPs) in 3' UTRs of genes may affect miRNA binding to messenger RNA and contribute to the risk of disease.²⁸ mGluR1 mRNA is increased in prefrontal cortex.²⁹ Similarly, SNPs in MiR219-1 and MiR137 are associated with schizophrenia.³⁰ A study in postmortem specimens of schizophrenic patient brains showed protein expression of mGluR5, as well as Norbin and Tamalin in hippocampal CA1 region of schizophrenia subjects.³¹ Norbin and Tamalin are modulator of mGluR5 signalling and trafficking. Production of oligonucleotides against these proteins




Figure 4: Showing role of miRNA in post transcriptional modification

Table 1: Showing genes involved in schizophrenia		
Gene	Function	miRNA
DISC 1	Disrupted in schizophrenia 1: By its interaction with other proteins, it is involved in neural growth and brain development. It was found in many Scottish families. Gene translocation was noted at t(1:11)(q42.1;q14.3)	Let-7f, miR-18b, miR-510, miR-188, miR-502
NRG1	Neuregulin 1: Interacts with the NEU/ ERB2 receptor tyrosine kinase to increase its phosphorylation on tyrosine residues and helps in neuronal, epithelial, and glial cells' growth and differentiation	miR-505
RGS4	Regulator of G protein signaling 4: It regulates signaling upstream or at the level of heteromeric G protein.	mir-18b, mir-502

RGS4: Regulator of G protein signaling 4

may be a promising for schizophrenia. Among these genes important ones include COMT, glutamic acid decarboxylase 67, and DRD2. Recent studies using microarray shown identified many other genes, including RGS4, 2',3'-cyclic nucleotide 3'-phosphodiesterase, and oligodendrocyte-lineage transcription factor 2.³² Genes such as GRM3, G72, DAAO, CHRNA7, PRODH,PPP3CC associated with NMDAR.²¹ In certain studies that related to pre-miRNAs' processing mutant alleles were detected which points that these microRNAs may results in development of schizophrenia.³³

One of the risk factors for schizophrenia is 22q11.2 deletion. Here, 22q11.2-associated microRNA dysregulation during brain development in the postnatal period, up-regulation of a neural tissue maturation inhibitor, *Mirta22/Emc10* occurs and results in a defect in protein synthesis. This has been demonstrated in *Mirta22* knockout mice.³⁴ Defects in miRNAs altering the interactions between miRNAs and their mRNA targets may contribute to schizophrenia.³³ Typically, miRNA 19 is implicated in schizophrenia.³⁵ However, the biological roles of miRNAs *in vivo* remain largely unknown. In particular, the physiological and

pathological roles of individual microRNAs in the brain have not been investigated extensively, although expression profiles of microRNAs have been reported in many given conditions. In a recent study, authors identified miR-19, which is enriched in adult hippocampal neural progenitor cells (NPCs), as a key regulator for adult hippocampal neurogenesis. miR-19 is an intrinsic factor regulating the migration of newborn neurons by modulating the expression level of RAPGEF2. After observing the abnormal expression patterns of miR-19 and RAPGEF2 in NPCs derived from induced pluripotent stem cells of schizophrenic patients, which display aberrant cell migration, authors proposed miR-19 as a molecule associated with schizophrenia. The results illustrate that a single microRNA has the potential to impact the functions of the brain. Identifying miRNA-mediated posttranscriptional gene regulation in the brain will expand our understanding of brain development and functions and the etiologies of several brain disorders.²⁶

Aptamers are already found be having a role as diagnostic biomarkers in fields of cancer, Alzheimer's disease.³⁶⁻³⁸ Since there is no biomarker for diagnosing schizophrenia it can be hypothesized to introduce an aptamer as a biomarker for diagnosing schizophrenia. New genes that are related to neuropsychiatric disorders include the retinoic acid-related orphan receptor alpha gene and the microRNA MIR137; former attributed to autism spectrum disease and the later to schizophrenia.³⁹ It has been shown that regulation of miR-137 is important for neural functioning while its disruption may be related to expression of schizophrenia. By genome-wide association studies show that risk for schizophrenia have an association with SNPs within the MIR137 gene locus.⁴⁰

Due to the deficit of biomarkers for the diagnosis of schizophrenia, psychiatrists follow clinical evaluation for the management of the disease. However, recently, it has been hypothesized that exosomal miRNAs, which are resistant to degradation can be isolated easier and further can be used as a biomarker for the disease.⁴¹ It was found in mice that expression of BACE 1 cleaved the neuregulin 1 gene related to schizophrenia.⁴² inhibition of BACE 1 activity by DNA aptamers is already demonstrated.⁴³

CONCLUSION

Even though aptamers are started in the therapeutics of some neurological diseases like macular degeneration, its application in neuropsychiatric diseases is yet to be explored. Genetics of schizophrenia is still challenging. Aptamers can be targeted against the proteins produced by the abnormal gene, which itself is the pathogenesis of schizophrenia.

REFERENCES

- Charlson FJ, Ferrari AJ, Santomauro, DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: Findings from the global burden of disease study 2016. *Schizophr Bull.* 2018;44(6):1195-1203. <https://doi.org/10.1093/schbul/sby058>
- TextBook_Of_Biological_Psychiatry_-_Jaak_Panksepp_2004_.pdf. Available from: https://social.stoa.usp.br/articles/0016/2390/textbook_of_biological_psychiatry_-_jaak_panksepp_2004_.pdf [Last accessed on 2016 Sep 06].
- Emsley R, Chiliza B, Asmal L and Harvey BH. The nature of relapse in schizophrenia. *BMC Psychiatry.* 2013;13:50. <https://doi.org/10.1186/1471-244X-13-50>
- Fischer BA and Carpenter WT. Will the Kraepelinian dichotomy survive DSM-V? *Neuropsychopharmacology.* 2009;34(9):2081-2087. <https://doi.org/10.1038/npp.2009.32>
- Howes OD and Kapur S. The dopamine hypothesis of schizophrenia: Version III—the final common pathway. *Schizophr Bull.* 2009;35(3):549-562. <https://doi.org/10.1093/schbul/sbp006>
- Kapur S and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. *Prog Neuropsychopharmacol Biol Psychiatry.* 2003;27(7):1081-1090. <https://doi.org/10.1016/j.pnpbp.2003.09.004>
- Howes OD, Kambaitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. *Arch Gen Psychiatry.* 2012;69(8):776-786. <https://doi.org/10.1001/archgenpsychiatry.2012.169>
- Boley AM, Perez SM and Lodge DJ. A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia. *Schizophr Res.* 2014;157(1-3):238-243. <https://doi.org/10.1016/j.schres.2014.05.005>
- Javitt DC. Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia. *Curr Treat Options Psychiatry.* 2015;1(2):107-120. <https://doi.org/10.1007/s40501-014-0010-9>
- Stępnicki P, Kondej M and Kaczor AA. Current concepts and treatments of schizophrenia. *Molecules.* 2018;23(8):2087. <https://doi.org/10.3390/molecules23082087>
- Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, Pisu MG, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. *Proc Natl Acad Sci U S A.* 1998;95(26):15718-15723. <https://doi.org/10.1073/pnas.95.26.15718>
- Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM and McGuire PK. Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. *Br J Psychiatry Suppl.* 2007;51:S13-S18. <https://doi.org/10.1192/bjp.191.51.s13>
- Parashar A. Aptamers in therapeutics. *J Clin Diagn Res.* 2016;10(6):BE01-BE06. <https://doi.org/10.7860/JCDR/2016/18712.7922>
- McConnell EM, Holahan MR and DeRosa MC. Aptamers as promising molecular recognition elements for diagnostics and therapeutics in the central nervous system. *Nucleic Acid Therapeutics.* 2014;24(6):388-404.
- Chandola C, Kalme S, Casteleijn MG, Urtti A and Neerathilingam M. Application of aptamers in diagnostics, drug-delivery and imaging. *J Biosci.* 2016;41(3):535-561. <https://doi.org/10.1007/s12038-016-9632-y>
- Mannironi C, Di Nardo A, Fruscoloni P and Tocchini-Valentini GP. *In vitro* selection of dopamine RNA ligands. *Biochemistry.* 1997;36(32):9726-9734. <https://doi.org/10.1021/bi9700633>
- AlShamaileh H and Veedu RN. Next-generation nucleic acid aptamers with two-base-modified nucleotides have improved binding affinity and potency. *Chembiochem.* 2017;18(16):1565-1567. <https://doi.org/10.1002/cbic.201700276>
- Holahan MR, Madularu D, McConnell EM, Walsh R and DeRosa MC. Intra-accumbens injection of a dopamine aptamer abates MK-801-induced cognitive dysfunction in a model of schizophrenia. *PLoS One* 2011;6:e22239.
- Veedu R, editor. *Aptamers: Tools for Nanotherapy and Molecular Imaging.* Singapore: Pan Stanford; 2023. Available from: <https://www.crcpress.com/Aptamers-Tools-for-Nanotherapy-and-Molecular-Imaging/Veedu/p/book/9789814669832> [Last accessed on 2023 Jul 11].
- Rentmeister A, Bill A, Wahle T, Walter J and Famulok M. RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 *in vitro*. *RNA.* 2006;12(9):1650-1660. <https://doi.org/10.1261/rna.126306>
- Wang Y, Khaing ZZ, Li N, Hall B, Schmidt CE and Ellington AD. Aptamer antagonists of myelin-derived inhibitors promote axon growth. *PLoS One.* 2010;16;5:e9726. <https://doi.org/10.1371/journal.pone.0009726>
- Ulrich H, Ippolito JE, Pagan OR, Eterovic VA, Hann RM, Shi H, et al. *In vitro* selection of RNA molecules that displace cocaine from the membrane-bound nicotinic acetylcholine receptor. *Proc Natl Acad Sci U S A.* 1998;95(24):14051-14056. <https://doi.org/10.1073/pnas.95.24.14051>
- Lakhin AV, Tarantul VZ and Gening LV. Aptamers: Problems, solutions and prospects. *Acta Naturae.* 2013;5(4):34-43.
- Karayiorou M and Gogos JA. Schizophrenia genetics: Uncovering positional candidate genes. *Eur J Hum Genet.* 2006;14(5):512-519. <https://doi.org/10.1038/sj.ejhg.5201587>
- Chaumette B, Kebir O and Krebs MO. Genetics and epigenetics of schizophrenia and other psychoses. *Biol Aujourdhui.* 2017;211(1):69-82. <https://doi.org/10.1051/jbio/2017015>
- Harrison PJ and Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. *Mol Psychiatry.* 2004;10(1):40-68.
- Talbot K, Eidem WL, Tinsley CL, Benson MA, Thompson EW, Smith RJ, et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. *J Clin Invest.* 2004;113(9):1353-1363. <https://doi.org/10.1172/JCI20425>
- Gong Y, Wu CN, Xu J, Feng G, Xing QH, Fu W, et al. Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets. *Eur Neuropsychopharmacol.* 2013;23(10):1182-1189. <https://doi.org/10.1016/j.euroneuro.2012.12.002>
- Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL and Meador-Woodruff JH. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. *Synapse.* 2005;57(3):123-131.

- <https://doi.org/10.1002/syn.20164>
30. Sun YJ, Yu Y, Zhu GC, Sun ZH, Xu J, Cao JH, et al. Association between single nucleotide polymorphisms in MiR219-1 and MiR137 and susceptibility to schizophrenia in a Chinese population. *FEBS Open Bio*. 2015;5:774-778.
<https://doi.org/10.1016/j.fob.2015.08.008>
 31. Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, et al. Metabotropic glutamate receptor 5, and its trafficking molecules Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. *Schizophr Res*. 2015;166(1-3):212-218.
<https://doi.org/10.1016/j.schres.2015.05.001>
 32. Kleinman JE, Law AJ, Lipska BK, Hyde TM, Ellis JK, Harrison PJ, et al. Genetic neuropathology of schizophrenia: New approaches to an old question, and new uses for postmortem human brains. *Biol Psychiatry*. 2011;69(2):140-145.
<https://doi.org/10.1016/j.biopsych.2010.10.032>
 33. Feng J, Sun G, Yan J, Noltner K, Li W, Buzin CH, et al. Evidence for X-chromosomal schizophrenia associated with microRNA alterations. *PLoS One*. 2009;4(7):e6121.
<https://doi.org/10.1371/journal.pone.0006121>
 34. Diamantopoulou A, Sun Z, Mukai J, Xu B, Fenelon K, Karayiorgou M, et al. Loss-of-function mutation in Mirta22/Emc10 rescues specific schizophrenia-related phenotypes in a mouse model of the 22q11.2 deletion. *Proc Natl Acad Sci U S A*. 2017;114(30):E6127-E6136.
<https://doi.org/10.1073/pnas.1615719114>
 35. Han J and Gage FH. A role for miR-19 in the migration of adult-born neurons and schizophrenia. *Neurogenesis (Austin)*. 2016;3(1):e1251873.
<https://doi.org/10.1080/23262133.2016.1251873>
 36. Ranjan R, Esimbekova EN and Kratasyuk VA. Rapid biosensing tools for cancer biomarkers. *Biosens Bioelectron*. 2016;87: 918-930.
<https://doi.org/10.1016/j.bios.2016.09.061>
 37. Scarano S, Lisi S, Ravelet C, Peyrin E and Minunni M. Detecting Alzheimer's disease biomarkers: From antibodies to new biomimetic receptors and their application to established and emerging bioanalytical platforms-a critical review. *Anal Chim Acta*. 2016;940:21-37.
<https://doi.org/10.1016/j.aca.2016.08.008>
 38. Ngo D, Sinha S, Shen D, Kuhn EW, Keyes MJ, Shi X, et al. Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease. *Circulation*. 2016;134(4):270-285.
<https://doi.org/10.1161/CIRCULATIONAHA.116.021803>
 39. Devanna P and Vernes SC. A direct molecular link between the autism candidate gene RORa and the schizophrenia candidate MIR137. *Sci Rep*. 2014;4:3994.
<https://doi.org/10.1038/srep03994>
 40. Warburton A, Breen G, Bubb VJ and Quinn JP. A GWAS SNP for schizophrenia is linked to the internal MIR137 promoter and supports differential allele-specific expression. *Schizophr Bull*. 2016;42(4):1003-1008.
<https://doi.org/10.1093/schbul/sbv144>
 41. Raghavan V, Bhomia M, Torres I, Jain S and Wang KK. Hypothesis: Exosomal microRNAs as potential biomarkers for schizophrenia. *Med Hypotheses*. 2017;103:21-25.
<https://doi.org/10.1016/j.mehy.2017.04.003>
 42. Luo X, He W, Hu X and Yan R. Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice. *Biol Psychiatry*. 2014;76(2):120-127.
<https://doi.org/10.1016/j.biopsych.2013.09.026>
 43. Liang H, Shi Y, Kou Z, Peng Y, Chen W, Li X, et al. Inhibition of BACE1 activity by a DNA aptamer in an Alzheimer's disease cell model. *PLoS One*. 2015;10(10):e0140733.
<https://doi.org/10.1371/journal.pone.0140733>

Authors Contribution:

JPK- Design of the study, review of literature, analysis and preparing the manuscript, preparing the manuscript; **SC-** Review of literature; **PK-** Analysis and preparing the manuscript; **SSKG-** Analysis and preparing the manuscript.

Work attributed to:

Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Saveetha University, P.O. Thandalam, Chennai, Tamil Nadu, 602 105, India.

Orcid ID:

Dr. Jabir P. K. - <https://orcid.org/0000-0001-5962-9207>
Dr. Sai Sailesh Kumar Goothy - <https://orcid.org/0000-0002-5838-3994>

Source of Support: Nil, **Conflicts of Interest:** None declared.